Lactase Deficiency in 2026: Understanding Pathophysiology, Global Persistence Trends, and Targeted Therapies for Lactose Intolerance.

Lactose intolerance is a common digestive disorder found in many people around the world. It occurs when the body does not produce enough of the enzyme lactase needed to break down lactose, a type of sugar. Lactose is present in almost all mammal milk products, and for infants, this sugar is important for providing energy during their growth. There are many variations of adults with lactase persistence around the world; for example, in Nordic countries, more than 90% of adults produce lactase into adulthood, but in Southeast Asia, only around 10% of adults do so. Overall, about one-third of all adults can digest dairy products; however, many people believe that there will be negative side effects if they eat or drink dairy products. This leads to a restriction of dairy products that can hurt the body's ability to grow and get enough nutrients because dairy products contain many essential nutrient sources (protein, vitamins, minerals). About 68% of the world population is affected by lactose intolerance, but that figure has not changed much in the past decade. However, there are vast regional variations (5-28% in Europe and 70-98% in Asia and Africa). The therapeutic market, including enzyme supplements, probiotics, and dietary aids applicable in all of the severity stages of the condition, is estimated to be valued at $ 36.96 billion in 2026, which represents a 7.4% compound annual growth rate; to reach $ 49.13 billion in 2030 due to the creation of personalized interventions and dairy substitutes.